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cutaneous manifestations not directly related to NTMs. There was no specific
time-sequence in the appearance of zoster, salmonellosis and NTM infec-
tions. Three different clinical courses were recorded and most of our pa-
tients (75.8%) required long-term anti-mycobacterial therapy.
Conclusions: Despite anti-mycobacterial therapy, the clinical course of most
patients with anti-IFN-g autoantibodies and dNTM infections is protracted
and recalcitrant. In addition to microbial infections, the other common clin-
ical presentations include neutrophilic dermatoses and T-cell/macrophage
linage-associated malignancies. In the future, further study is needed to
elucidate the characteristics of this disease.
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Purpose: Through this study to understand the status and efficacy of imple-
mentation of latent tuberculosis infection (LTBI) treatment program in our
hospital during 3 years period.
Methods: Including cases fit the criteria for national LTBI treatment program
from 2011 to Aug. 2014 under 13 years/old, through descriptive statistics to
understand the current status and efficacy in our hospital.
Results: The total number of cases exanimated in our hospital was 657, and
numbers fit the criteria for inclusion was 545 (82.9%). Positive tuberculin skin
test (TST) within first month was 190 cases (35%), and positive conversion at
the third month 139 cases (39%), totally 329 cases need to be treat for LTBI.
Family accepted to start LTBI treatment was 230 (85%), and the number that
should completed treatment at the end of this study was 203, and actual
completed treatment was 200 (98.5%).
Conclusion: Taiwan is country with high burden of TB, the treatment of
latent tuberculosis infection is an important strategy to further reducing
tuberculosis occurrence. During study period, we found 2 new TB cases via
contact screening in 2011, and 3 cases had side effect of itchy skin. We think
detailed and repeat education to the families with comprehensive case man-
agement and follow-up is the most important methods to improve the
compliance and efficacy of LTBI treatment program.
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SALVAGE THERAPY FOR REFRACTORY PULMONARY TUBERCULOSIS BY
TREATING CMV PNEUMONIA: A CASE REPORT
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Purpose: Cytomegalovirus (CMV) infection occurs in 0 to 36% of critically ill
patients, mostly between 4 and 12 days after intensive care units (ICUs)
admission. Co-infection of miliary tuberculosis and CMV infection was re-
ported in Taiwan. We report a case of pulmonary tuberculosis (TB) with
delayed negative conversion of acid-fast bacilli probably due to co-infection
of CMV.
Case report: A 66-year-old man of liver cirrhosis suffered from respiratory
distress. Laboratory data showed leukocytosis (WBC: 19,900/mL); and C-
reactive protein, >250 mg/L. Chest CT showed suspicious TB. Acid-fast stain
(AFS) showed positive (4+). He was admitted to intensive care unit (ICU) on
July 29, 2014. He received endotracheal tube insertion with mechanical
ventilator use due to respiratory failure. CXR showed multiple opacities
were noticed in bilateral lung fields, compatible with TB infection. Antibi-
otics with Tazocin and anti TB with rifater and ethambutol were given.
Anti-TB therapy changed to rifinah and pyrazinamide due to liver function
impairment. Streptomycin was given from August 23 to September 17,
2014, due to persistent positive AFS. MTB Quantitative PCR showed 107
CFU/mL and no RIF Resistance. Blood and sputum CMV-PCR showed positive,
CMV viral load showed 258 IU/mL. Aspergillus Ag showed 0.23 Index. Anti-
CMV treatment with ganciclovir iv was used for 2 weeks. MTB QuantitativePCR showed 107 CFU/mL and no RIF Resistance. Blood and sputum CMV-
PCR showed not detected, CMV viral load showed <137 IU/mL. Then valgan-
ciclovir po was used for 4 weeks for CMV pneumonitis. Left pneumothorax
happened and pig-tail was inserted from August 9 to August 25, 2014. He
was transferred to RCC due to ventilator dependent on August 25, 2014.
CXR showed no pneumothorax on October 14, 2014. Sputum AFS was still
positive and we added antibiotic with levofloxacin for pulmonary TB and
sputum culture showed Stenotrophomonas maltophilia. Minocin oral form
was prescribed for sputum. After treatment, lung condition got much
improvement. He was transferred to RCW for ventilator department.
Conclusion: CMV co-infection could be considered for patients with refrac-
tory pulmonary TB and anti-CMV therapy may improve clinical outcome.PS 2-526
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Purpose: Autoantibodies against IFN-g is an emerging medical issue and linked
to disseminatedmycobacterial infections and other opportunistic infections in
the Southeast Asia. The origin of these autoantibodies is unclear; however, the
majority of affected patients share specificHLA class II alleles and this observa-
tion suggests a common mechanism in the production of auto-antibodies may
exist. Persistent or refractory infection seems to be the consequence of pa-
tients with disseminated non-tuberculous mycobacterial (NTM) infection and
concurrent anti-IFN-g autoantibodies even received anti-NTMantibiotics treat-
ment. Depletion of autoantibody to IFN-g by rituximab (anti-CD20) therapy
were been reported in some patients and they had clinical and laboratory evi-
dence of clearance of infection and diminished anti-IFN-g autoantibody. How-
ever, more evidences are required to show the efficacy and cost-effectiveness
of B cells depletion therapy in this disease.
Methods: We presented clinical courses of 3 patients (P1-3) with dissemi-
nated NTM infection and concurrent anti-IFN-g autoantibodies. Besides stan-
dard anti-NTM antibiotics treatment, they all received four doses of
rituximab therapy. The titers of anti-IFN-g auto-antibodies, ex vivo IL-
12p40 production in whole blood stimulated by IFN-g, inflammatory titers,
and clinical response in these 3 patients after rituximab therapy were
analyzed.
Results: P1 and P2 showed no significant difference of anti-IFN-g autoanti-
body titer in blocking assay (efficacy 50%) and had no response to exogenous
IFN-g stimulation in whole blood samples after received the rituximab ther-
apy. However, P3 had decreased the blocking titer and showed a significant
response to endogenous IFN-g activation in term of IL-12p40 production. Un-
expectedly, all 3 patients presented with shrinkage sizes of involved lymph
nodes by computer tomography (CT) study despite of consistent autoanti-
bodies levels in P1 and P2. P1 and P3 had continued anti-NTM antibiotics
treatment for 19 months and 30 months, respectively. P2 had cutaneous
NTM infection and disappeared 2 months after rituximab therapy, when
completed 3-month anti-NTM antibiotics. However, P2 had recurrence of
cutaneous lesions 5 months after discontinuing antibiotics. P3 had cervical
spondylitis involving C5 and C6 with compression signs around 6 months after
rituximab therapy. CT-guide biopsy showed negative culture for NTM, indi-
cated immune reconstitution syndrome-related progressive of symptoms,
rather than recurrence of NTM infection.
Conclusion: We showed here the clinical benefit of rituximab therapy in
combined with antibiotic regime in three patients with disseminated NTM
infection and concurrent anti-IFN-g autoantibodies. The improvement of
clinical signs might not associate with the decreasing of anti-IFN-g autoanti-
bodies measured in vitro. Short-course regime of rituximab therapy might
have good efficacy and cost-effectiveness to treat this disease.
